HeartBeam (BEAT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.82 mm	5.82 mm	5.82 mm	5.82 mm	5.82 mm	5.82 mm
Cash burn (monthly)	1.13 mm	1.12 mm	1.69 mm	1.59 mm	1.10 mm	1.10 mm
Cash used (since last report)	4.81 mm	4.75 mm	7.20 mm	6.77 mm	4.70 mm	4.68 mm
Cash remaining	1.01 mm	1.07 mm	-1.38 mm	-944.14 k	1.13 mm	1.14 mm
Runway (months of cash)	0.9	1.0	-0.8	-0.6	1.0	1.0

Beta Read what these cash burn values mean

Financial data from HeartBeam earnings reports.

Institutional ownership, Q3 2024

BEAT institutional ownership history Ownership history

28.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	24	32	-25.0%
Opened positions	5	7	-28.6%
Closed positions	13	3	+333.3%
Increased positions	5	7	-28.6%
Reduced positions	1	5	-80.0%

13F shares	Current	Prev Q	Change
Total value	4.80 bn	5.80 bn	-17.3%
Total shares	7.64 mm	7.82 mm	-2.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Strome Mark E	2.90 mm	$6.50 mm	0.0%
Public Ventures	2.62 mm	$0.00	0.0%
Vanguard	750.71 k	$1.74 bn	+5.2%
Smith, Salley & Associates	250.00 k	$580.00 mm	0.0%
Geode Capital Management	233.40 k	$541.60 mm	+9.5%
O'shaughnessy Asset Management	139.18 k	$314.55 mm	NEW
Ritholtz Wealth Management	139.18 k	$322.90 mm	NEW
Kestra Private Wealth Services	103.62 k	$240.40 mm	+13.9%
Cannon Financial Strategists	80.39 k	$186.51 mm	0.0%
BlackRock	74.65 k	$173.18 mm	NEW

Largest transactions	Shares	Bought/sold	Change
UBS UBS	0.00	-160.00 k	EXIT
O'shaughnessy Asset Management	139.18 k	+139.18 k	NEW
Ritholtz Wealth Management	139.18 k	+139.18 k	NEW
Beacon Pointe Advisors	0.00	-133.33 k	EXIT
SF Stifel Financial	0.00	-100.00 k	EXIT
BlackRock	74.65 k	+74.65 k	NEW
STT State Street	0.00	-69.57 k	EXIT
Spectrum Asset Management	54.40 k	-52.80 k	-49.3%
BLK BlackRock	0.00	-51.44 k	EXIT
Vanguard	750.71 k	+36.86 k	+5.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BEAT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Sep 24	Urioste George De	Common Stock	Sell	Dispose S	No	No	2.34	1,674	3.92 k	57,146
30 Aug 24	Urioste George De	Common Stock	Sell	Dispose S	No	No	2.31	5,500	12.71 k	58,820
27 Aug 24	Urioste George De	Common Stock	Sell	Dispose S	No	No	2.26	2,194	4.96 k	64,320
26 Aug 24	Urioste George De	Common Stock	Sell	Dispose S	No	No	2.38	300	714.00	66,514
23 Aug 24	Urioste George De	Common Stock	Sell	Dispose S	No	No	2.3	2,500	5.75 k	66,814

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target

15 Nov 24

Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:BEAT) with a Speculative Buy and maintains $8 price target.

Press releases

From Benzinga Pro

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

29 Jan 25

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

23 Dec 24

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment The Company is gearing up for an Early Access Program to gain initial commercialization

HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

16 Dec 24

First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device

HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference

19 Nov 24